Want to see SABS full AI Analyst Report?
SABS Stock Chart & Stats
$3.85
$0.50(13.16%)
At close: 4:00 PM EST
$3.85
$0.50(13.16%)
Day’s Range― - ―
52-Week Range$1.85 - $6.60
Previous CloseN/A
Volume58.44K
Average Volume (3M)398.22K
Market Cap
$302.80M
Enterprise Value$22.55M
Total Cash (Recent Filing)$107.39M
Total Debt (Recent Filing)$6.17M
Price to Earnings (P/E)8.8
Beta0.96
Next Earnings
Aug 06, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding76,464,096
10 Day Avg. Volume357,955
30 Day Avg. Volume398,221
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.27
Enterprise Value/Ebitda7.67
Forecast
1Y Price Target
$12.00Price Target Upside211.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Tc Bovine Antibody PlatformThe unique Tc bovine platform is a durable competitive asset that enables generation of high‑titer, fully human polyclonal antibodies. This platform can underpin multiple programs, attract partnerships and non‑dilutive funding, and create high switching costs for competitors over the medium term.
Low Leverage / Relatively Strong Balance SheetVery low debt reduces near‑term solvency risk and preserves financial optionality, giving management flexibility to fund trials, negotiate partnerships, or access capital without immediate liquidity pressure. This structural balance sheet strength extends runway versus more leveraged peers.
Manufacturing Pact And Advancing Clinical ProgramA committed manufacturing partner and defined post-approval spend terms materially de‑risk a commercialization path for SAB‑142. Combined with ongoing Phase 2b enrollment and positive Phase 1 signals, this operational readiness supports a credible route to scale if regulatory approval is achieved.
Bears Say
Near-zero Revenue And Negative Gross ProfitAbsence of recurring product revenue means the business lacks internal cash generation to fund operations. Persistent negative gross profit also indicates the current cost structure cannot support margin sustainability until a commercial product is approved and scaled.
Material Negative Operating And Free Cash FlowSustained cash burn and deeply negative free cash flow create ongoing funding requirements, increasing dilution or dependency on milestone payments and grants. This structural cash gap constrains development pacing and raises execution risk for multi‑year clinical programs.
Business Reliant On Collaborations, Grants And Milestone FundingAs a clinical‑stage company, revenue is lumpy and contingent on partnerships, milestones and grants. This structural dependency increases timing and execution risk, making long‑term program continuity sensitive to external funding and partner decisions.
SAB Biotherapeutics News
SABS FAQ
What was SAB Biotherapeutics’s price range in the past 12 months?
SAB Biotherapeutics lowest stock price was $1.85 and its highest was $6.60 in the past 12 months.
What is SAB Biotherapeutics’s market cap?
SAB Biotherapeutics’s market cap is $302.80M.
When is SAB Biotherapeutics’s upcoming earnings report date?
SAB Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were SAB Biotherapeutics’s earnings last quarter?
SAB Biotherapeutics released its earnings results on May 12, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.212 by -$0.138.
Is SAB Biotherapeutics overvalued?
According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued.
Does SAB Biotherapeutics pay dividends?
SAB Biotherapeutics does not currently pay dividends.
What is SAB Biotherapeutics’s EPS estimate?
SAB Biotherapeutics’s EPS estimate is -0.28.
How many shares outstanding does SAB Biotherapeutics have?
SAB Biotherapeutics has 76,464,096 shares outstanding.
What happened to SAB Biotherapeutics’s price movement after its last earnings report?
SAB Biotherapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.212. Following the earnings report the stock price went down -2.688%.
Which hedge fund is a major shareholder of SAB Biotherapeutics?
Currently, no hedge funds are holding shares in SABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SAB Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (211.69% Upside)
$12.00 (211.69% Upside)
Hedge Fund Trend
Increased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.05%
12-Months-Change
Fundamentals
Return on Equity
-0.29%
Trailing 12-Months
Asset Growth
551.81%
Trailing 12-Months
Company Description
SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SABS Earnings Call
Q1 2026
0:00 / 0:00
SABS Stock 12 Month Forecast
Average Price Target
$12.00
▲(211.69% Upside)
Technical Analysis
Ownership Overview
17.39% Insiders
3.41% Mutual Funds
68.17% Other Institutional Investors
5.26% Public Companies and
Individual Investors